Results 21 to 30 of about 2,193 (158)
Pretomanid-resistant tuberculosis
Journal of Infection, 2023 Contains fulltext : 292381.pdf (Publisher’s version ) (Closed access)
Niklas Koehler +24 more
openaire +4 more sources
A NEW ANTI-TUBERCULOSIS DRUG PRETOMANID FOR THE TREATMENT OF DRUG-RESISTANT TB (REVIEW)
Актуальные проблемы теоретической и клинической медицины, 2023 The review used 61 literature sources on the new anti-tuberculosis drug PA-824-pretomanid, which exhibits antimicrobial activity against strains of drug-resistant Mycobacterium tuberculosis.
G. Smailova
doaj +1 more source
Туберкулез и болезни лёгких, 2021 The article presents the review of 68 publications, recommendations, and guidelines on clinical trials of pretomanid for the treatment of patients with drug resistant tuberculosis. According to the publications, combinations of pretomanid with other anti-
A. V. Kukurika
doaj +1 more source
Can a new nitroimidazole knockout the unconquered tuberculosis?
Archives of Medicine and Health Sciences, 2020 Pretomanid (PA-824) is the latest drug to get approval from the United States Food and Drug Administration (FDA) for the treatment of tuberculosis (TB).
Dhyuti Gupta +2 more
doaj +1 more source
Population Pharmacokinetics of the Antituberculosis Agent Pretomanid [PDF]
Antimicrobial Agents and Chemotherapy, 2019 A population pharmacokinetic (PopPK) model for pretomanid was developed using data from 14 studies in the pretomanid development program: six phase 1 studies, six phase 2 studies, and two phase 3 studies. The final analysis data set contained 17,725 observations from 1,054 subjects, including healthy subjects and subjects with drug-sensitive, multidrug-
Salinger, David H. +3 more
openaire +2 more sources
Novel 6-Month Treatment for Drug-Resistant Tuberculosis, United States
Emerging Infectious Diseases, 2021 The US Food and Drug Administration approved a 6-month regimen of pretomanid, bedaquiline, and linezolid for extensively drug-resistant or multidrug-intolerant tuberculosis after a trial in South Africa demonstrated 90% effectiveness 6 months ...
Connie A. Haley +11 more
doaj +1 more source
Dynamic 18F-Pretomanid PET imaging in animal models of TB meningitis and human studies
Nature Communications, 2022 Pretomanid has been approved for use in cases of multi-drug resistant pulmonary tuberculosis, yet the penetration of this antibiotic into other target tissues is not well established.
Filipa Mota +15 more
doaj +1 more source
Male reproductive hormones in patients treated with pretomanid
The International Journal of Tuberculosis and Lung Disease, 2022 BACKGROUND: Pretomanid (Pa) is a nitroimidazole-class drug recently approved by the US Food and Drug Administration and other regulatory authorities as part of a regimen for treating highly drug-resistant pulmonary Mycobacterium tuberculosis infections.
Boekelheide, K. +7 more
openaire +2 more sources
Pretomanid for tuberculosis treatment: an update for clinical purposes
Current Research in Pharmacology and Drug Discovery, 2022 Coronavirus disease (COVID-19) pandemic determined a 10 years-set back in tuberculosis (TB) control programs. Recent advances in available therapies may help recover the time lost. While Linezolid (LZD) and Bedaquiline (BDQ), previously Group D second line drugs (SLDs) for TB, have been relocated to Group A, other drugs are currently being studied in ...
Occhineri S. +6 more
openaire +3 more sources
Туберкулез и болезни лёгких, 2021 The article presents a review of 70 publications. It describes relevant data on drugs, timing, indications, efficacy, and safety of short-term treatment regimens for multiple drug resistant tuberculosis.
A. E. Russkikh +4 more
doaj +1 more source